Altimmune (ALT) Research & Development (2010 - 2026)

Altimmune (ALT) has 17 years of Research & Development data on file, last reported at $16.2 million in Q1 2026.

• Research & Development for Q1 2026 came in at $16.2 million, up 2.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.8 million (down 12.76% YoY), and the FY2025 annual result was $66.4 million, down 19.21% from the prior year.
• Research & Development retreated to $16.2 million in Q1 2026 per ALT's latest filing, from $18.4 million in the prior quarter.
• Over five years, Research & Development peaked at $21.5 million in Q1 2024 and troughed at $13.3 million in Q2 2023.
• A 5-year average of $17.7 million and a median of $17.2 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development slumped 30.62% in 2022, then surged 59.62% in 2024.
• A 5-year view of Research & Development shows it stood at $19.2 million in 2022, then dropped by 11.84% to $16.9 million in 2023, then rose by 16.99% to $19.8 million in 2024, then retreated by 6.94% to $18.4 million in 2025, then declined by 12.04% to $16.2 million in 2026.
• Business Quant data shows ALT's Research & Development at $16.2 million in Q1 2026, $18.4 million in Q4 2025, and $15.0 million in Q3 2025.